Norway· NO-ID_31E1E738-90D9-4CC0-BC11-494AA165DA29
Camzyos
A mavacamten product containing mavacamten, registered in Norway by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 15 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Mavacamten is registered in 15 of 19 countries.
Countries holding a registration under ATC C01EB24 (mavacamten), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Mavacamten · ATC C01EB24
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mavacamten costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mavacamten · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$118.52
The record
At a glance
FEST (Norway)- Active substance
- Mavacamten
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Norway (NO)
- ATC code
- C01EB24
- ATC class
- Mavacamten
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_31E1E738-90D9-4CC0-BC11-494AA165DA29
- no_varenummer43569628NOK 19050.2
- gtin8027950800544
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mavacamten in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCAMZYOSBristol-Myers Squibb Pharma EEIG, Dublin
- CanadaCAMZYOSBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandCamzyos
- SpainCAMZYOS 10 MG CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- FinlandCAMZYOSBristol-Myers Squibb Pharma EEIG
- FranceCAMZYOS 10 mg, géluleBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomCamzyos 10mg capsulesBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandCamzyos 10 mg Capsule hardBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Camzyos
- Liechtenstein · Camzyos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1d9a3d3d-9285-43f8-bfb3-610d2513670c GET /v1/drugs/1d9a3d3d-9285-43f8-bfb3-610d2513670c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsel, hard",
"source": "fest",
"status": "A",
"atc_name": "Mavakamten",
"merkevare_id": "ID_31E1E738-90D9-4CC0-BC11-494AA165DA29",
"name_form_strength": "Camzyos kaps 10 mg",
"prescription_group": "C"
}See everything about mavacamten.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.